by Janssen with support from Havas Lynx
by The Hepatitis C Trust
by ALK-Abelló Ltd
by LJWG with support from Dovetail Strategies funded by: Janssen, MSD, Reckitt Benckiser Pharmaceuticals, and Roche Products
by Novo Nordisk A/S with support from Lagos State Government, General Hospital Ikorodu and Sunny Kuku Foundation
by Otsuka Pharmaceutical Europe Ltd. with support from Apothecom, a Huntsworth Health Company
by Janssen with support from Havas Lynx
SEPT, a UK leader in the provision of mental health and community services, and Janssen, with its long heritage in psychiatry, came together to explore potential opportunities for joint working. Having identified shared values and strategic priorities they agreed to work together to test an innovative model of disease management in the UK that had the potential to significantly improve the pathway for people with schizophrenia, bipolar and affective disorders. This exciting undertaking placed digital innovation at the core, allowing aligned interests and shared values to deliver transformational innovation in healthcare provision and improved outcomes for patients. To date, the Maintaining Adherence Programme (MAP) has delivered: outstanding patient, carer and staff experience/satisfaction results, considerable reduction in hospital admissions and significant improvements in efficiency/cost savings.
We really liked this effective collaboration between Janssen and SEPT to address the massive societal impact of poor adherence in patients with schizophrenia. We saw tangible and impressive patient outcomes in the form of significantly reduced hospital admissions and bed days - both fulfilling the QIPP agenda.
Entry deadline | 26 August 2022 |
Extended entry deadline | 2 September 2022* *additional fee applies |
Judging Day | 6 October 2022 |
Company/Team of the Year Interviews | 21 October 2022 |
PMEA Event | 23 November 2022 |